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Abstract. Natural products have been acknowledged for 
numerous years as a vital source of active ingredients in 
therapeutic agents. In particular, the use of active ingredients 
derived from plants for use in microbial natural products have 
long been used before the dawn of modern medicine. From 
ancient times, the efficacy of natural products has been associ-
ated with the chemistry, biochemistry and synthetic activities 
of natural products. Thus, with scientific advancement in 
modern molecular and cellular biology, analytical chemistry 
and pharmacology, the unique properties of these natural prod-
ucts are being harnessed in order to exploit the chemical and 
structural diversity and biodiversity of these types of products 
in relation to their therapeutic effect. Often, new molecules 
of interest in drug design units focus on the rearrangement of 
chemical entities or structural isomers of naturally occurring 
products in order to generate new molecules; these may be 
formulated into clinically useful therapies.
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1. Introduction
A natural product is a chemical entity, formed by a naturally 
occurring living organism with pharmacological properties, 
which may contribute to vital drug discovery and design. The 
crude substance extracted from the body of medicinal plants, 
animals, microbes or microorganism fermentation broths 
contains unique and structurally diverse chemical compo-
nents. Natural products have been vital in pharmaceutical and 
biotechnology industries, as a vast range of modern medi-
cines are based upon either naturally occurring molecules, 
or derivatives of these. Generally, the therapeutic agents that 
are inhaled, ingested and injected are a mixture of complex 
therapeutic compounds.
2. Sources of drugs
The complexity of the therapeutic agents depends on the 
mixture of chemicals prepared synthetically. Therapeutic 
agents are considered as natural, synthetic, or semi-synthetic 
dependent on the source from which they were generated (1). 
The natural environment remains a significant origin of novel 
therapeutic agent compounds. Natural therapeutic agents are 
prepared from compounds found occurring in nature, which 
contain active components in extract form created from 
sources, including plants, microbes, minerals and animals. 
The most dominant natural medicine source is plants, due to 
their chemical and structural diversity and the biodiversity 
of their components. Examples of medicines that are derived 
from plants are aspirin (from willow tree bark) (2), digoxin 
(from the flower, Digitalis lanata) (3) and morphine (from 
opium) (4). Indeed, it is projected that in the industrialized 
nation, >60% of all medicines are either natural products or 
secondary metabolites thereof (5). Although there are chal-
lenges from different, novel drug discovery methods, natural 
products continue to produce additional clinical candidates and 
medicinal compounds. These compounds remain an important 
foundation of novel medicines, particularly in anti-infective 
[azitromycin (6) and amphotericin B (7), acyclovir (8) and 
romidepsin] (9) therapies. Many have subsequently advanced 
into clinical trials or onto the market (4). The expansion of 
novel technologies (high throughput screening, automated 
separation methods and combinatorial chemistry) in drug 
discovery has transformed the screening of natural products 
due to their chemical and structural diversity and biodiver-
sity (10).
The distinctive structural diversity of natural compounds 
is advantageous during the production of combinatorial 
libraries using semi-synthetic methods. Semi-synthetic thera-
peutic agents are a hybrid of natural and synthetic sources. 
Semi-synthetic therapeutic agents are generally produced 
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by transforming starting materials from natural sources 
into final products via chemical reactions (11). Examples of 
semi-synthetic medicines are antibiotic penicillin (12) and 
paclitaxel (an anticancer drug derived from the Pacific yew 
tree, Taxus brevifolia) (13).
3. Current uses of natural product drugs
The importance of natural products used in the treatment 
and prevention of human diseases may be evaluated by the 
following: The introduction of novel, chemical, diverse enti-
ties with their application as patterns for semi-synthetic and 
total synthetic modification; the quantity of diseases treated by 
these diverse compounds; and their rate of use in the treatment 
of diseases (14). Natural products continue to be the focus 
of pharmaceutical research, due to the failure of substitute 
drug discovery methods to provide many lead compounds in 
vital therapeutic areas, such as anti-infective and metabolic 
diseases. Research into natural products continues to provide 
a novel template for drug discovery of lead compounds for 
the pharmaceutical industry. Currently, it is undisputed that 
natural products have been, and will be, key sources of innova-
tive pharmaceutical therapeutic agents. The drug metabolites 
produced from synthetic drug sources exert fewer therapeutic 
effects with adverse side effects. Synthetic therapeutic agents 
are comprised of small chemical building blocks, which 
are not found in nature, but are produced with the help of 
computer-based research, such as computational chemistry 
and using various chemical sources, such as arterolane 
(anti-malaria drug) (15). However, therapeutic agents formed 
from natural sources may avoid the side effects, as they 
produce physiological and pharmacological effects within 
living cells. In addition, natural products have a wider distribu-
tion of molecular properties, such as lower molecular mass, 
partition coefficient and structural diversity (16). Moreover, 
natural products have more interaction with proteins, enzymes 
and other biological molecules. Furthermore, natural products 
contain fewer heavy metals and have greater molecular rigidity 
when compared with synthetic compounds and combinatorial 
libraries (13).
4. Natural product drug development
Although natural products have been vital in drug discovery, 
recently pharmaceutical companies have either terminated or 
substantially reduced their natural product research (13). The 
reason for this is the development of advanced techniques, 
such as metagenomics, combinatorial chemistry and high 
throughput screening. Furthermore, not all natural prod-
ucts can be completely synthesized, due to their structural 
complexity and as the process would be time consuming 
and expensive. However, with the help of advanced drug 
discovery and increased medicinal chemistry knowledge, the 
pharmaceutical and biotech industries are once again turning 
to natural products in order to harness new useful entities or 
derivatives of these in therapeutics. Often, this is driven by 
therapeutic need in difficult to treat diseased states or clinical 
conditions such as cancer, obesity and infection activated by 
multi-resistant pathogens. Plants, microorganisms, fungi and 
bacteria have been invaluable in drug design and continue 
to be a rich source of natural products in the drug discovery 
process. The war against various multi-resistant pathogens 
requires advanced and more effective therapeutic agents. Only 
5-15% of terrestrial plants out of the existing 250,000 species 
have been chemically and pharmacologically scrutinized in 
resourceful mode for use as therapeutic agents. Furthermore, 
the microbial domain signifies 90% of all natural diversity, 
however <1% has been discovered (13). Currently, the threat of 
extinction of natural diversity due to environmental reasons, 
such as global warming and toxic waste (including heavy 
metals and cyanides) from synthetic compounds and multi-
drug resistance to traditional medicines is high. Therefore, 
it is considered to be particularly important to establish the 
importance of natural diversity and bioresources to educate 
current research strategies in biotechnological and large phar-
maceutical companies for use in the drug discovery process.
The objective of all drug discovery processes is to estab-
lish the most promising lead compounds, which may be used 
as a therapeutic agent and facilitated with treating medical 
conditions, including infections, cancer, nervous system 
diseases, high blood pressure and metabolic diseases (13). 
During the early stages of the drug design process, scien-
tists must isolate and purify the lead compounds from their 
natural source by utilizing various methods depending on the 
structural diversity, stability and quantity of the compound 
required. High throughput screening has been used to screen 
the lead compounds against specific targets. Subsequent to 
vital biochemical and pharmacological tests, the promising 
compounds for the specific targets are selected. At this phase 
in the drug design process, many lead compounds are not 
selective enough for their target molecule. In a bid to improve 
their selectivity, scientists modify the lead compound struc-
tures as per the expected structure-activity relationships. 
If the modifications increase the selectivity, the promising 
compounds move to in vitro and in vivo testing in designated 
disease facsimiles (15). Upon a positive result, scientists are 
required to conduct safety tests on the selected compounds 
to establish the mechanism by which the drug is absorbed, 
distributed, metabolized and excreted. This process (termed 
pharmacokinetics) indicates the mechanisms that occur when 
the therapeutic agent enters the body. If all of the results and 
optimizations are positive, then lead compounds may become 
potential candidate drugs (13).
5. Future directions for natural product drug discovery
Biological diversity and modern genomics are crucial topics 
leading bioscience in the 21st century, and biodiversity is 
considered to be increasingly important in this field (17). 
Indeed, natural products are full of biodiversity, the research of 
which requires extensive and in-depth experience, particularly 
in taxonomy, which takes time to accrue. Pharmaceutical and 
biotechnology companies must adapt to the immediate need for 
new medicines and adopt new techniques in order to overcome 
clinical conditions that cannot be treated using conventional 
therapies. Hence, looking into the structure-activity relation-
ships of naturally occurring active ingredients may offer a 
strategy to overcome such medicinal challenges. By contrast, if 
industries want to contribute to, and take advantage of, the drug 
discovery process, then they must establish techniques, such as 
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computational chemistry, to achieve more sustainable use of 
their natural resources. Industries must realize that although 
natural products perform important biological functions with 
a valuable role in the ecosystem, their economic value may be 
less until their primary utility is exposed and established. To 
understand the utility and important benefits, pharmaceutical 
industries must be prepared to contribute actively and finan-
cially to the drug discovery process (13). Natural products 
are considered to be particularly valuable for the production 
of various precious lead components ranging from simple 
chemical structures to highly complex structures. Natural 
metabolites are always superior in terms of biochemical and 
pharmacological activities when compared with secondary 
metabolites (18). The current drug discovery processes arising 
from natural resources is primarily focused on the isolation, 
purification, screening and discovery of novel drug candidates. 
In order to move forward with any potential lead compounds, 
large scale extraction or biotechnology production is required 
in order to move the lead compounds forward and make them 
clinically feasible.
In the revolutionized and highly competitive field of 
modern pharmaceutical research, natural products can mimic 
distinctive metabolites of biological functionality such as 
hormones and naturally occurring ligands (19) as well as 
possessing great structural diversity, which is necessary for 
the drug discovery process. To regenerate the interest of the 
pharmaceutical industry and, in order to be competitive with 
other advanced drug discovery techniques, natural product 
research must constantly increase the efficiency of screening 
(computational or otherwise), isolation, robotic separation 
and purification. Additionally, drug stability and formulation 
studies as well as efficacy, pharmacokinetics and metabolic 
engineering investigations are required in order to identify 
compounds of interest and move them forward into clinically 
applicable therapies. The growing demand for medicinal 
plants in traditional and herbal medicine is also threatening 
their existence. To improve biodiversity across the globe, it is 
critical to cultivate medicinal plants using controlled and scien-
tific methods, to provide the desired medicinal plants at high 
quality. In addition, toxic waste from the production process 
greatly impacts the biological ecosystem; it has particularly 
harmful effects on the plants and aquatic life in streams (20). 
To protect the natural resources, toxic waste containing toxic 
elements and unpleasant, odor-producing chemicals must be 
separated and treated independently. This protection of the 
natural flora will aid in the sustainability of ecosystems and 
hence protect any natural resource that may be used for the 
discovery of unique medicinal and biological metabolites.
6. Conclusions
An integrative approach of coupling advanced genetic 
sequencing with the management of biosynthetic pathways, 
may deliver a sustainable and realistic route for the future 
discovery of pharmaceutical drug candidates. The success of 
natural products in past and present drug discovery is funda-
mentally associated with their complex structural diversity, 
as well as advancement in understanding of how structural 
confirmations or functionality contribute to molecular activity 
in biomedicine. Nature continues to provide biological diver-
sity, which is important to target, particularly considering the 
insufficient results obtained from combinatorial techniques. It 
is hoped that the environment will continue to provide undis-
covered resources, permitting the unique discovery of novel 
weapons against developing infections.
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